The study is a dose-escalation, open-label, multiple-dose trial to evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.
The study aims for twice-weekly dosing of patients for 6 weeks followed by a safety data review period before escalating to a higher dose level in a new group of patients.
The principal investigator in the study at Mayo is John Lust.
Senesco president and CEO Leslie Browne said they have collaborated for several years with Lust to study SNS01-T and its predecessors before selecting their lead candidate.